Paid clinical trial for healthy Sub-Saharan Black African volunteers aged 18-45
Receive a payment for your time!
We are carrying out a clinical trial with two marketed drugs that are being developed in combination for the prevention of seasonal malaria in children. The main aim of this study is to determine how safe and well tolerated the drugs are when given in combination to healthy volunteers. The results of this study may be used to support further drug development for the prevention of malaria.
This study will be conducted at our clinical trials unit in London Bridge and will involve healthy volunteers of sub-Saharan African origin (i.e your family comes from a sub-Saharan country although both you and/or your parents could have been born in the United Kingdom)
If your family originated from any of these countries [view here] you could be eligible to take part
You will need to attend a screening visit within 20 days before the start of the study. If successful, you will be required to be in our unit for one in house stay of 5 days / 4 nights, four outpatients visits on Days 8, 15, 22 and 29 and one final follow-up visit on Day 36 (see dates in detail below)
The aim of this study is to determine how safe and well-tolerated the drugs are when given in combination to healthy volunteers. The results of this study may be used to support further drug development for the prevention of malaria.
Study dates – Cohort 5
* Only 1 screening appointment necessary during screening period
Who can take part?
To be eligible to take part in this study you must fit the following criteria:
- Healthy Black males and females of sub-Saharan African origin aged between 18 and 45 (inclusive).
- You must have a Body Mass Index (BMI) within the range 18.0-25.0 kg/m² (inclusive).
- You must not consume tobacco in any form or other nicotine-containing products 3 months before you receive the first study drug administration.
- You must be healthy with no underlying medical conditions that may either interfere with participation in the clinical study, and/or put you at any significant risk.
- You must not be on any regular medications, including over the counter medications.
- You must not have donated or lost blood within 16 weeks before you receive the first study drug administration.
- You must not have travelled to a malaria endemic region for more than a total of 4 weeks in the past 12 months.
- Female volunteers of childbearing potential, if heterosexually active, must agree to the use of highly effective contraception starting from one complete menstrual cycle prior to the first day of dosing and continuing until at least 90 days after the last study drug administration.
- Male volunteers must be willing to use appropriate contraception for the duration of the study and continuing until at least 3 months after the last study drug administration. Female spouses or partners of the male volunteer must be willing to use appropriate contraception starting at least one complete menstrual cycle prior to the first day of dosing and continuing until at least 90 days after the last study drug administration.
- Additionally, You must agree not to donate sperm or ova (eggs) from the time of the first study drug administration until 3 months after study drug administration.
A full list of acceptable contraceptive methods will be discussed in full by a member of the recruitment team and a study doctor during screening.
In recognition of the time involved in taking part in this study, you will receive £1,528 (£458 bonus and £1,070 study payment) on completion of the study provided you comply fully with all the study requirements. This amount is based on the anticipated study plan and will be adjusted pro-rata (i.e. same amount of money paid per unit of time), should we invite you to attend extra visits.
Get in touch
Call our team for more information on: +44 (0) 20 7042 5800 (opt 1)
We are open weekdays 9am-5pm
or email us: firstname.lastname@example.orgRegister your interest in this clinical trial
Ref: C18034_Jan 2019 (email_website_advert text)
The contents of this email have been approved by an ethics committee. Any response to this advertisement will be recorded. Your response will not place you under any obligation to participate in this trial.
You may be required to remain resident in the unit until resolution of any safety issues, after which you will be discharged from the unit.